ALK and adenocarcinoma: In a study on 114 patients affected by adenocarcinoma or not otherwise specified lung cancer, Cicek et al. (15) found adequate material for EGFR mutation in 88.6%, for ALK and ROS1 rearrangement, respectively in 93.8% and 91.8%.